CompletedPhase 3

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

United States, Germany, Italy68 participantsStarted 2014-06

Plain-language summary

Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.

Who can participate

Age range5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Completed study TIRCON2012V1 Exclusion Criteria: * Withdrew from the study TIRCON2012V1 for reasons of safety * Plan to participate in another clinical trial at any time from the day of enrolment until 30 days post-treatment in the current study

What they're measuring

Number of Participants With Adverse Events

Timeframe: 18 months

Trial details

NCT IDNCT02174848

SponsorApoPharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-03-16

Results submitted2019-05-01

View on ClinicalTrials.gov More Pantothenate Kinase-Associated Neurodegeneration trials